Implication of Sperm RNA in Transgenerational Inheritance of the Effects of Early Trauma in Mice

June 4, 2014

Recent studies have suggested that early-life stressors and traumatic experiences can cause heritable changes in gene expression in future generations. Researchers at the University of Zurich’s Brain Research Institute hypothesized that early-life stressors in male mice may cause heritable changes in the small, non-coding RNA content (including miRNAs) in the sperm of traumatized mice and […]

Read the full article →

mrSNP: Software to detect SNP effects on microRNA binding

March 18, 2014

mrSNP is a highly adaptable and performing web based tool for predicting the effect a 3′UTR SNP will have on miRNA binding. This tool has advantages over existing algorithms because it can assess the effect of novel SNPs on miRNA binding without requiring significant hands on time. Project home page: http://mrsnp.osu.edu License: Free for commercial […]

Read the full article →

Workshop: “NGS and non-coding RNA data analysis”

March 5, 2014

The organizers are happy to announce the upcoming “NGS and non-coding RNA data analysis” workshop II (2014) 15-16 May, Plovdiv, Bulgaria The SeqAhead COST action BM1006 is organizing a 2 day workshop with presentations on non-coding RNA (ncRNA) research, bioinformatics, data analysis and stimulating discussions between biologists and bioinformaticians. The registration for this COST WS is now […]

Read the full article →

Discussion of miRNA Gene Expression Normalization Strategies

March 5, 2014

Researchers at the University of Oxford and the Scripps Research Institute recently published an article evaluating the use of several different RT-qPCR normalization strategies when profiling miRNA gene expression in mouse serum. In their research article entitled “Assessment of RT-qPCR Normalization Strategies for Accurate Quantification of Extracellular microRNAs in Murine Serum,” Roberts et. al. compare […]

Read the full article →

MicroRNA 491-3p & Pharmacogenetics: Regulation of UDP-Glucuronosyltransferase 1A1 Expression and Activity

February 10, 2014

The goal of pharmacogenetics is to better understand human response to both environmental toxins and drug treatment. Recently, several laboratories have investigated the hypothesis that microRNA regulation of drug metabolizing enzymes may influence their expression and ultimately effect enzymatic activity and patient drug toxicities. Researchers at the Pennsylvania State Hershey College of Medicine and Washington […]

Read the full article →

starBase update: deciphering Pan-Cancer patterns of miRNAs, lncRNAs, ceRNAs and RNA-binding proteins from TCGA 14 cancer types

February 8, 2014

StarBase has been updated to explore Pan-Cancer pattern of lncRNAs, miRNAs, RNA-binding proteins (RBP) and their regulatory networks (ceRNA, coexpression) by mining expression profiles of miRNAs, lncRNAs and mRNAs across 14 cancer types (>6000 samples) from The Cancer Genome Atlas (TCGA) Data Portal (all data available without limitations). StarBase provides the following Pan-Cancer Analysis Services: […]

Read the full article →

DiamiR Reports Validation of Two Families of Brain-Enriched microRNAs as Highly Promising Blood-Based Biomarkers of Mild Cognitive Impairment

January 2, 2014

MONMOUTH JUNCTION, NJ–(Marketwired – January 02, 2014) - DiamiR, LLC, a molecular diagnostics company focused on the development and commercialization of innovative blood-based tests for detection and monitoring of neurodegenerative diseases and cancer, announced today the publication entitled “Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study” in Aging. Mild Cognitive Impairment is a […]

Read the full article →

Marina Biotech and Mirna Therapeutics Amend License Agreement for the Development of microRNA-Based Therapeutics

January 2, 2014

Mirna Broadens Rights to Its Lead Cancer Therapeutic Candidate MRX34 BOSTON, MA and AUSTIN, TX–(Marketwired – Jan 2, 2014) – Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company, and Mirna Therapeutics, Inc. (Mirna), a privately-held biotechnology company pioneering microRNA (miRNA) replacement therapy for cancer, announced today that they have amended their […]

Read the full article →

Rosetta Genomics Granted U.S. Patent Allowance for the Use of microRNAs to Treat Liver Cancer

November 7, 2013

Expands the Company’s Patent Portfolio in Oncology Therapeutics PRINCETON, NJ and REHOVOT, ISRAEL–(Marketwired – Nov 7, 2013) – Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces receipt of a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) related to U.S. Patent Application No. 13/481,105 titled “Targeting […]

Read the full article →

microRNA-122: Positive Preclinical Profile of a GalNAc-conjugated anti-miR Supports Clinical Development for the Treatment of HCV

November 4, 2013

Regulatory Application for RG-101 to be Filed in the Near Term: Clinical Studies in Man Expected to Commence in Early 2014 LA JOLLA, Calif., Nov. 4, 2013 /PRNewswire/ — Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that data demonstrating the positive preclinical profile of […]

Read the full article →